GlaxoSmithKline plans to hire former AstraZeneca and Novartis finance director Jonathan Symonds to manage its breakup, according to the Financial Times.
Mr. Symonds' appointment closes a six-month search to replace Sir Philip Hampton. Mr. Hampton has been nonexecutive chairman of GSK since 2015.
Mr. Symonds, deputy group chairman of financial services company HSBC, has vast experience in pharmaceutical transactions. He will oversee the demerging of GSK's consumer division into a joint venture with Pfizer. The rest of GSK will be a standalone pharmaceutical and vaccines company.
Mr. Symonds previously served as CFO at Novartis from 2009-13, and spent a decade at AstraZeneca until 2007, according to the Financial Times.
Read more here.
More articles on pharmacy:
Judge blocks HHS rule requiring drug prices in TV ads
Nation's 1st prescription drug affordability board goes into effect
11 healthcare pharma leaders offer advice on controlling drug spend